Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund

SAN DIEGO, Aug. 20, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
August 09, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Reports Second Quarter 2012 Results

SAN DIEGO, Aug. 9, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
July 02, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Scheduling of End-of-Phase 2 Meeting With FDA for MN-221 for the Treatment of Acute Exacerbations of Asthma

SAN DIEGO, July 2, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
July 02, 2012 18:30 ET | Source: MediciNova, Inc.

MediciNova to Present at the JMP Securities Seventh Annual Healthcare Conference

SAN DIEGO, July 2, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
May 23, 2012 16:00 ET | Source: MediciNova, Inc.

MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations

Company Intends to Move Forward With End-of-Phase 2 Meeting With FDA and Phase 3 Clinical Development Management to Host Conference Call to Discuss Results Today, May 23rd at 5:00pm (EDT) SAN...
May 10, 2012 17:30 ET | Source: MediciNova, Inc.

MediciNova Reports First Quarter 2012 Results

SAN DIEGO, May 10, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
April 23, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain

SAN DIEGO, April 23, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
April 10, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Appoints David O'Toole CPA to its Board of Directors

SAN DIEGO, April 10, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
March 29, 2012 06:15 ET | Source: MediciNova, Inc.

MediciNova Reports Fourth Quarter and Full Year 2011 Results

SAN DIEGO, March 29, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange...
March 22, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Management to Host a Conference Call to Discuss 2011 Earnings Thursday, March 29th at 5:00 P.M. (EDT)

SAN DIEGO, March 22, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...